October 22, 2025

Retrospective Evaluation of Dosing Effects of Bumetanide Continuous Infusions in the Pediatric Cardiac Intensive Care Unit.

SNSukumar Suguna NarasimhuluUF Health Shands Hospital BWBriana J. WilliamsNorthwestern University BKBrian KellyUniversity of Newcastle Australia

Key Points

Bumetanide continuous infusion achieved negative fluid balance in pediatric cardiac ICU patients within 24 hours, with notable efficacy.
Median dose of bumetanide was 0.046 mg/kg/hr over an average duration of 5.8 days, across 90 pediatric patients in the study.
No clinically significant changes were observed in serum electrolytes or creatinine levels during the study, indicating safety.
However, high doses over 0.1 mg/kg/hr did not improve patient outcomes, suggesting the need for further research in neonates.

Abstract

Bumetanide is commonly used to achieve diuresis and alleviate fluid overload in pediatric cardiac intensive care unit (PCICU) patients. This study aims to describe the dosing, efficacy, and safety of bumetanide continuous infusion (CI) regimens used in PCICU patients. This single center, retrospective study included patients 0.1 mg/kg/hr may not improve the overall outcome, and future studies can explore specific advantages of its use in neonates undergoing cardiac surgery.

Perguntar à IA

Bookmark

View Full Paper